Skip to content

Search

Efficacy of human papillomavirus 16 and 18 vaccine against cervical cancer: Final randomized, double-blind PATRICIA trial

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine in...

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: Combined analysis of data from the Costa Rica Vaccine and PATRICIA trials

The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV

Protective anti-outer membrane protein immunity against Pasteurella pneumotropica infection of mice

The proteins examined were the homologues of the P4, P6, P26, and D15 proteins of Haemophilus influenzae.

Crowding and other strong predictors of upper respiratory tract carriage of otitis media-related

We investigated predictors of nasopharyngeal carriage in Australian Aboriginal and non-Aboriginal children.

The safety of maternal immunization

Existing evidence supporting the safety of vaccination during pregnancy should be used to reassure pregnant women and improve vaccine uptake in pregnancy

Influenza epidemiology, vaccine coverage and vaccine effectiveness in children admitted to sentinel Australian hospitals in 2014

The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance programme operating in all states and territories in Australia

Latest news & events

Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.

Warm Welcome for the Neonatal Infection and Immunity Team

Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.

Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents

This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents.